ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO208

CXCL5 Inhibition Attenuates Diabetic Kidney Disease in a Mouse Model of Type 2 Diabetes Mellitus

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Chang, Ting-Ting, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan
  • Chen, Ching, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan
  • Chen, Jaw-Wen, Taipei Veterans General Hospital, Taipei, Taiwan
Background

Diabetic kidney disease (DKD) is typically characterized by progressive proteinuria and decreasing glomerular filtration rate, which might finally progress to end stage renal disease. Chemokines are critically involved in the inflammatory progression in the development of DN. CXC motif chemokine ligand 5 (CXCL5), a CXC type chemokine, is found upregulated in clinical and experimental diabetes mellitus (DM). Given the potential involvement of CXCL5 in the development or progression of DKD, this study sought to investigate the direct impacts of CXCL5 inhibition on DKD in experimental type 2 DM.

Methods

Leprdb/JNarl type 2 DM mice were used for a mouse model of DKD. Mice were randomly assigned to receive an anti-CXCL5 neutralizing monoclonal antibody or a control antibody for 4 weeks. Serum blood urea nitrogen (BUN), creatinine (Cre), and uric acid levels were examined before and after the treatment. Urinary albumin-to-creatinine ratio (UACR) and kidney-to-body weight ratio were measured. Renal glomerulosclerosis and fibrosis were also evaluated by Periodic acid-Schiff staining and Masson's trichrome staining after the treatment.

Results

Serum CXCL5 concentrations, body weight, and blood glucose levels were upregulated in the DKD mice. Serum BUN, Cre, and uric acid levels that were enhanced in DKD mice with a control antibody were decreased in mice treated with an anti-CXCL5 antibody. The UACR and kidney-to-body weight ratio were attenuated by the treatment of anti-CXCL5 antibodies compared to that of control antibodies. Furthermore, glomerular hypertrophy, glomerulosclerosis, and renal fibrosis were also reduced in DKD mice that received the anti-CXCL5 antibody.

Conclusion

Our pilot findings suggested that in vivo CXCL5 inhibition could improve renal function and reduce urinary albumin-to-creatinine ratios, glomerular hypertrophy, glomerulosclerosis, and renal fibrosis in DKD mice. The molecular mechanistic insights may be further explored to provide a novel theoretical basis for CXCL5 as a potential therapeutic target in DKD.